Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | CASP1 | P29466 | 1/20 | 0.68 |
| ▸ | CASP7 | P55210 | 1/20 | 0.68 |
| ▸ | EGFR | P00533 | 5/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470940 | 1.00 | KDM4E (0.68) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL28156296 | 0.84 | ALDH1A1 (0.53) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL17561039 | 0.83 | KDM4E (0.69) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL5211637 | 0.82 | ALDH1A1 (0.68) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL7463580 | 0.81 | KDM4E (0.71) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL4975424 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL5062953 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL379103 | 0.81 | KDM4E (1.00) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL29612371 | 0.81 | KDM4E (1.00) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL5063952 | 0.81 | ALDH1A1 (0.66) | KDM4EALDH1A1GAAMAPTCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114828648-A | Pet food compositions | 希尔氏宠物营养品公司 | 2022-07-29 | — | — | CN | claimed |
| CN-109328018-A | Adjust the composition and method of the intracorporal phosphorus of companion animals or enzyme | 雀巢产品技术援助有限公司 | 2019-02-12 | — | — | CN | claimed |
| CN-104204798-A | Biomarkers for bladder cancer and methods using the same | METABOLON INC | 2014-12-10 | — | — | CN | claimed |
| CN-1938018-A | Use of compounds capable of increasing serum IGF-1 levels for the preparation of therapeutic compositions for the treatment of various disease states associated with decreased IGF-1 serum levels in humans and animals | VEIJLEN LTD (AN) | 2007-03-28 | — | — | CN | claimed |
| JP-8151367-A | — | — | None | — | — | JP | disclosed |
| CN-114828648-A | Pet food compositions | 希尔氏宠物营养品公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-109328018-A | Adjust the composition and method of the intracorporal phosphorus of companion animals or enzyme | 雀巢产品技术援助有限公司 | 2019-02-12 | — | — | CN | disclosed |
| CN-104204798-A | Biomarkers for bladder cancer and methods using the same | METABOLON INC | 2014-12-10 | — | — | CN | disclosed |
| CN-1938018-B | Use of compounds for the preparation of compositions for the treatment of various disease states in humans and animals associated with reduced IGF-1 serum levels | VEIJLEN LTD | 2010-09-01 | — | — | CN | disclosed |
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| CN-1938018-A | Use of compounds capable of increasing serum IGF-1 levels for the preparation of therapeutic compositions for the treatment of various disease states associated with decreased IGF-1 serum levels in humans and animals | VEIJLEN LTD (AN) | 2007-03-28 | — | — | CN | disclosed |
| CN-1870992-A | Animal feed composition | VEIJLEN N V (AN) | 2006-11-29 | — | — | CN | disclosed |
| US-20060166983-A1 | Indole derivatives as ppar modulators | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | disclosed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1581491-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004092131-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-1224275-A2 | MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS | Incyte Genomics, Inc. (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001021836-A2 | MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS | INCYTE GENOMICS, INC. (US) | 2001-03-29 | — | — | WO | disclosed |
| JP-H08151367-A | PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE REACTION, AND NEW COMPOUND | CERBIOS PHARMA SA | 1996-06-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166983-A1 | Indole derivatives as ppar modulators | PPARA, PPARD, PPARG | KDM4E 2086/4885ALDH1A1 1181/4885GAA 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.